Amphastar Pharmaceuticals (AMPH) Cash & Current Investments (2013 - 2026)

Amphastar Pharmaceuticals' Cash & Current Investments history runs 14 years deep, the most recent figure standing at $171.1 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 6.47% year-over-year to $171.1 million in Q1 2026; TTM through Mar 2026 was $171.1 million, a 6.47% decrease from a year earlier, with the FY2025 full-year figure at $170.4 million, up 10.79% from the prior year.
• Cash & Current Investments held at $171.1 million in Q1 2026 per AMPH's latest filing, from $170.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $271.0 million in Q3 2023 and bottomed at $144.5 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $172.8 million (2022), against an average of $181.3 million.
• Across the five-year window, Cash & Current Investments surged 69.99% in 2023 and fell 29.04% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $156.3 million in 2022, then decreased by 7.57% to $144.5 million in 2023, then advanced by 6.45% to $153.8 million in 2024, then increased by 10.79% to $170.4 million in 2025, then advanced by 0.43% to $171.1 million in 2026.
• Per Business Quant, the three latest AMPH Cash & Current Investments figures stand at $171.1 million (Q1 2026), $170.4 million (Q4 2025), and $216.5 million (Q3 2025).